- Home
- SCYX vs ESLA Comparison
SCYX vs ESLA Comparison
Compare SCYX & ESLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCYX | ESLA |
|---|---|---|
| Founded | 1999 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.4M | 45.6M |
| IPO Year | 2014 | N/A |
Fundamental Metrics
Financial Performance| Metric | SCYX | ESLA |
|---|---|---|
| Price | $3.76 | $0.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $3.00 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 78.7K | 43.7K |
| Earning Date | 05-06-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.36 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $257,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $608.78 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.57 | $0.73 |
| 52 Week High | $5.62 | $3.15 |
Technical Indicators
Market Signals| Indicator | SCYX | ESLA |
|---|---|---|
| Relative Strength Index (RSI) | 43.82 | 36.89 |
| Support Level | $3.68 | $0.73 |
| Resistance Level | $5.10 | $1.28 |
| Average True Range (ATR) | 0.37 | 0.09 |
| MACD | -0.16 | -0.00 |
| Stochastic Oscillator | 3.18 | 16.76 |
Price Performance
Historical ComparisonAbout SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.
About ESLA Estrella Immunopharma Inc.
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.